Matches in SemOpenAlex for { <https://semopenalex.org/work/W2750797376> ?p ?o ?g. }
Showing items 1 to 100 of
100
with 100 items per page.
- W2750797376 endingPage "266" @default.
- W2750797376 startingPage "263" @default.
- W2750797376 abstract "ObjectiveTo analyze the efficacy and safety of conditioning regimen with busulfan and increased-dose of fludarabine for allogenetic hematopoietic stem cell transplantation (allo-HSCT) in intermediate and high- risk myeloid leukemia.MethodsA total of 111 cases of intermediate and high-risk myeloid leukemia receiving allo-HSCT from Jan. 2007 to Dec. 2015 were retrospectively analyzed. Conditioning regimen consisted of busulfan (4 mg/kg.day orally or 3.2 mg/kg.day intravenously for 3 days) with total dose of 200 mg/m2 fludarabine (by intravenous infusion, divided into 5-8 days). For patients with unrelated and mismatched related donors, total dose of 7.5-10 mg/kg rabbit antithymocyte globulin (by intravenous infusion, divided into 4 days) was added to the conditioning regimen. GVHD prophylaxis consisted of cyclosporine A, short-term MTX and mycophenolatemofetial (MMF).ResultsNeutrophil with ANC >0.5×109/L was achieved in 100% of recipients with median time of 13 days (range: 9-31 days) and platelet >20×109/L in 98.2% of recipients after a median of 16 days (range: 8-75 days). The cumulative incidence of grade Ⅱ to Ⅳ aGVHD was 39.6% and that of grade Ⅲ to Ⅳ aGVHD was 10.3%, and overall cGVHD was 21.0% with extensive cGVHD being apparent in 6.9%. The other complication included hemorrhagic cystitis (17.1%) and no hepatic veno-occlusive disease (VOD) was diagnosed. For all patients, 3-year overall survival (OS) and 3-year disease-free survival (DFS) was 78.8% and 77.6% respectively. For patients with complete remission, the 3-year OS was 88.6%, which was compared to that of 61.2% with advanced diseases (P=0.001). The overall cumulative rate of relapse was 18.3% with 7.3% for stable disease and 36.2% for advanced diseases (P<0.001).ConclusionBusulfan combined with increased-dose of fludarabine as conditioning regimen for allo-HSCT in AML patients can achieve stably hematopoietic reconstruction, has low toxicities and survival advantage. Such regimen can be used for transplantation in intermediate and high-risk myeloid leukemia and particularly recommended for patients with stable disease.Key words: Allogenetic hematopoietic stem cell transplantation; Conditioning regimen; Fludarabine; Acute myeloid leukemia" @default.
- W2750797376 created "2017-09-15" @default.
- W2750797376 creator A5007567606 @default.
- W2750797376 creator A5008731888 @default.
- W2750797376 creator A5014399133 @default.
- W2750797376 creator A5021882774 @default.
- W2750797376 creator A5028327040 @default.
- W2750797376 creator A5034594862 @default.
- W2750797376 creator A5051755939 @default.
- W2750797376 creator A5055303767 @default.
- W2750797376 creator A5056919239 @default.
- W2750797376 creator A5065243448 @default.
- W2750797376 creator A5065551912 @default.
- W2750797376 creator A5073141785 @default.
- W2750797376 creator A5073371361 @default.
- W2750797376 creator A5077970092 @default.
- W2750797376 creator A5078061801 @default.
- W2750797376 date "2016-05-20" @default.
- W2750797376 modified "2023-09-24" @default.
- W2750797376 title "Busulfan combined with increased-dose of fludarabine as conditioning regimen for allogeneic stem cell transplantation in intermediate and high-risk acute myeloid leukemia" @default.
- W2750797376 doi "https://doi.org/10.3760/cma.j.issn.0254-1785.2016.05.002" @default.
- W2750797376 hasPublicationYear "2016" @default.
- W2750797376 type Work @default.
- W2750797376 sameAs 2750797376 @default.
- W2750797376 citedByCount "0" @default.
- W2750797376 crossrefType "journal-article" @default.
- W2750797376 hasAuthorship W2750797376A5007567606 @default.
- W2750797376 hasAuthorship W2750797376A5008731888 @default.
- W2750797376 hasAuthorship W2750797376A5014399133 @default.
- W2750797376 hasAuthorship W2750797376A5021882774 @default.
- W2750797376 hasAuthorship W2750797376A5028327040 @default.
- W2750797376 hasAuthorship W2750797376A5034594862 @default.
- W2750797376 hasAuthorship W2750797376A5051755939 @default.
- W2750797376 hasAuthorship W2750797376A5055303767 @default.
- W2750797376 hasAuthorship W2750797376A5056919239 @default.
- W2750797376 hasAuthorship W2750797376A5065243448 @default.
- W2750797376 hasAuthorship W2750797376A5065551912 @default.
- W2750797376 hasAuthorship W2750797376A5073141785 @default.
- W2750797376 hasAuthorship W2750797376A5073371361 @default.
- W2750797376 hasAuthorship W2750797376A5077970092 @default.
- W2750797376 hasAuthorship W2750797376A5078061801 @default.
- W2750797376 hasConcept C126322002 @default.
- W2750797376 hasConcept C141071460 @default.
- W2750797376 hasConcept C2776694085 @default.
- W2750797376 hasConcept C2776755627 @default.
- W2750797376 hasConcept C2777408962 @default.
- W2750797376 hasConcept C2777600175 @default.
- W2750797376 hasConcept C2778729363 @default.
- W2750797376 hasConcept C2779263901 @default.
- W2750797376 hasConcept C2780611847 @default.
- W2750797376 hasConcept C2781413609 @default.
- W2750797376 hasConcept C2911091166 @default.
- W2750797376 hasConcept C71924100 @default.
- W2750797376 hasConcept C88879693 @default.
- W2750797376 hasConcept C90924648 @default.
- W2750797376 hasConceptScore W2750797376C126322002 @default.
- W2750797376 hasConceptScore W2750797376C141071460 @default.
- W2750797376 hasConceptScore W2750797376C2776694085 @default.
- W2750797376 hasConceptScore W2750797376C2776755627 @default.
- W2750797376 hasConceptScore W2750797376C2777408962 @default.
- W2750797376 hasConceptScore W2750797376C2777600175 @default.
- W2750797376 hasConceptScore W2750797376C2778729363 @default.
- W2750797376 hasConceptScore W2750797376C2779263901 @default.
- W2750797376 hasConceptScore W2750797376C2780611847 @default.
- W2750797376 hasConceptScore W2750797376C2781413609 @default.
- W2750797376 hasConceptScore W2750797376C2911091166 @default.
- W2750797376 hasConceptScore W2750797376C71924100 @default.
- W2750797376 hasConceptScore W2750797376C88879693 @default.
- W2750797376 hasConceptScore W2750797376C90924648 @default.
- W2750797376 hasIssue "5" @default.
- W2750797376 hasLocation W27507973761 @default.
- W2750797376 hasOpenAccess W2750797376 @default.
- W2750797376 hasPrimaryLocation W27507973761 @default.
- W2750797376 hasRelatedWork W2009504559 @default.
- W2750797376 hasRelatedWork W2069716413 @default.
- W2750797376 hasRelatedWork W2077684036 @default.
- W2750797376 hasRelatedWork W2136016420 @default.
- W2750797376 hasRelatedWork W2142338120 @default.
- W2750797376 hasRelatedWork W2273734510 @default.
- W2750797376 hasRelatedWork W2360634842 @default.
- W2750797376 hasRelatedWork W2393443446 @default.
- W2750797376 hasRelatedWork W2399925834 @default.
- W2750797376 hasRelatedWork W2414781517 @default.
- W2750797376 hasRelatedWork W2460663633 @default.
- W2750797376 hasRelatedWork W2466681359 @default.
- W2750797376 hasRelatedWork W2751801013 @default.
- W2750797376 hasRelatedWork W3004324041 @default.
- W2750797376 hasRelatedWork W3031445670 @default.
- W2750797376 hasRelatedWork W3031569017 @default.
- W2750797376 hasRelatedWork W3032226384 @default.
- W2750797376 hasRelatedWork W3184419037 @default.
- W2750797376 hasRelatedWork W869527191 @default.
- W2750797376 hasRelatedWork W1974637407 @default.
- W2750797376 hasVolume "37" @default.
- W2750797376 isParatext "false" @default.
- W2750797376 isRetracted "false" @default.
- W2750797376 magId "2750797376" @default.
- W2750797376 workType "article" @default.